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Abstract: 
Context- Multiple complex symptoms from cancer treatment can interfere with functioning. 
Objectives- To evaluate the efficacy of an “energy and sleep enhancement” (EASE) intervention 
to relieve fatigue and sleep disturbance and improve health-related functional status. 
Methods- Individuals receiving chemotherapy (CTX) were randomized to the EASE (n = 153) or 
a control intervention (n = 139). The EASE intervention included information and behavioral 
skills taught by an oncology nurse in three telephone sessions. The primary outcomes of fatigue, 
sleep disturbance, and functional status were measured before CTX, Day 4 after first treatment 
(baseline), and 43–46 or 57–60 days later (follow-up), depending on the CTX cycle length. 
Results- The sample was primarily female (82%) and non-Hispanic white (89%), with mean age 
of 53.9 years. Fatigue and patient-reported sleep disturbance were elevated in both groups at 
baseline and follow-up. Actigraphy revealed that the total sleep time was almost eight hours, and 
sleep percent was greater than 85% for both groups at both time points (normal range). Physical 
functioning was diminished and at the same level as a sample with serious illness. Mental 
functioning was in normal range. A repeated-measures analysis of variance revealed no 
statistically significant group-by-time effects for fatigue, sleep disturbance, or functional status. 
Unemployed individuals showed greater benefit from the EASE intervention, reporting less pain 
and symptom interference. 
Conclusion- Potential explanations include high variability and/or floor effect for fatigue, 
incorrect timing of measures, insufficient amount or dose of the intervention, and confounding 
effects of gender. Future research should consider screening for symptom severity and tailoring 
interventions. 
 
Article: 
INTRODUCTION 
Individuals with cancer often deal with multiple complex symptoms during cancer treatment that 
can interfere with functioning in usual roles and activities. However, research has typically 
focused on the alleviation of single symptoms, such as pain, fatigue, sleep disturbance, and 
depression. 1,2 Research is needed to examine the efficacy of intervention for multiple symptoms 
and determine whether intervention intended for one symptom will influence the severity of 
other symptoms. 
 
In the research presented here, four symptoms were chosen for consideration. Two symptoms—
fatigue and sleep disturbance—were targeted for intervention; the other two—pain and 
depression—were selected for observation. Cancer-related fatigue was a focus of this 
investigation, because a previous clinical trial demonstrated that training in energy conservation 
strategies significantly reduced fatigue.3 That study also showed that sleep disturbance was a 
significant problem during cancer treatment. Because sleep disturbance can increase fatigue, it 
was chosen for intervention in the current research. Two related symptoms, pain and depression, 
were chosen for evaluation in this research (but not targeted for intervention) because of a 
growing body of evidence linking them to cancer fatigue.4,5,6,7 The study was designed to extend 
past research systematically and incrementally by examining the effect of an intervention on the 
target symptoms (fatigue and sleep disturbance) and exploring how the related symptoms (pain 
and depression) might be influenced by the intervention. Thus, the aim of the research was to test 
the efficacy of an “energy and sleep enhancement” (EASE) intervention on the primary 
outcomes of fatigue, sleep disturbance, and functional status and the secondary outcomes of pain 
and depression. 
 
Past research has demonstrated that some symptoms influence other symptoms and have a 
negative effect on one or more symptom outcomes.1,2 Given et al. provided evidence that specific 
symptoms (fatigue, sleep disturbance, and pain) had different effects on outcomes when one, 
two, or all three symptoms were present. In one study, individuals who reported both pain and 
fatigue reported more symptoms overall than those who reported either symptom or neither 
symptom.8 In a separate analysis, pain, fatigue, and sleep disturbance were examined as 
predictors of functioning.9 Compared with no pain, fatigue, or sleep disturbance, individuals who 
had one, two, or all three symptoms had incrementally greater risk of impaired functioning 
during cancer therapy. Testing a mediation model, Beck et al.10 determined that pain influenced 
fatigue directly and also indirectly through its effect on sleep; this finding suggested that the use 
of better pain management to improve sleep could also decrease fatigue. The findings of these 
studies suggested that fatigue, sleep disturbance, and pain could be studied as a symptom cluster, 
because these symptoms tended to co-occur, and they influenced one another. 
 
Research has suggested that depression is related to the other symptoms of interest (in this 
context, “depression” refers to “depressive symptoms,” not a clinical diagnosis).7,11,12,13,14,15,16 
Some studies have demonstrated that depressive symptoms were influenced by other symptoms 
and changes in functioning. In a longitudinal study of outpatients with cancer, Williamson and 
Schulz17 demonstrated that, as pain increased and restricted activity, depressive symptoms also 
increased. Another study of fatigue and depression in cancer patients undergoing treatment 
demonstrated a similar result: There was a direct relationship between fatigue and depression as 
well as an indirect relationship between the two symptoms through the influence of fatigue on 
functional status.18 As fatigue increased and functioning in usual activities decreased, depressive 
symptoms increased. Because depressive symptoms have been associated with pain, fatigue, and 
functional status, it makes sense to examine these symptoms in the context of a symptom 
reduction intervention. 
 
Only a few symptom management studies have examined multiple symptoms.19,20,21 A 
comprehensive coping strategy intervention targeted to reduce pain, fatigue, nausea, and 
depression in breast cancer patients during autologous bone marrow transplant was associated 
with reduced nausea and fatigue seven days after transplant compared with a usual care group; 
pain, anxiety, and depression were not affected by the intervention.19 A structured symptom 
assessment for advanced lung cancer patients,21 conducted by research nurses and shared with 
clinic nurses, demonstrated a significant reduction in symptom distress after six sessions over a 
six-month period when compared with usual care.21 Finally, a cognitive behavioral intervention 
reduced symptoms during chemotherapy (CTX) when compared with usual care.20 Patients with 
greater symptom severity before treatment, who received the intervention, had lower symptom 
severity at Weeks 10 and 20 than a usual care control group. 
 
A few psychoeducational intervention studies aimed to reduce fatigue incorporated interventions 
to manage sleep disturbances. The results have been mixed. Yates et al. demonstrated better 
fatigue outcomes one week after completion of the intervention; however, the changes were not 
sustained over the next two cycles of treatment.22 Ream et al. documented better fatigue 
outcomes after three cycles of CTX; however, outcomes for the earlier cycles were not 
reported.23 Berger et al.24 evaluated the efficacy of a sleep management intervention to reduce 
fatigue and improve sleep quality; the intervention group had better sleep quality but not lower 
fatigue. The results to date do not provide conclusive guidance about the best strategies for 
management of fatigue and sleep disturbances. 
 
The study reported here extended a beneficial energy conservation and activity management 
(ECAM) intervention for fatigue to include intervention for sleep disturbance.3 In addition to the 
main analysis, the ECAM study showed that, after CTX treatment, 89% of the participants 
reported fatigue, 71% reported sleep disturbance, 30% reported pain, and 28% reported 
depression. Sixty-eight percent of those with fatigue also reported sleep disturbance, 30% 
reported pain, and 28% reported depression. These results provide an indication that other 
symptoms in addition to fatigue have been problematic during CTX and should be addressed in 
symptom research. 
 
METHODS 
Study Design 
The primary aim of this study was to test the efficacy of an EASE intervention during cancer 
CTX. The primary outcomes were fatigue, sleep disturbance, and functional status. The 
secondary outcomes were pain and depression. This randomized clinical trial compared the 
EASE intervention with an intervention controlling for time and attention that consisted of 
information about nutrition and a healthy diet. The study was conducted at four clinical sites: two 
university health science centers, a community cancer center, and a comprehensive cancer 
center. Individuals were eligible if they were 18 years of age or older and were beginning a new 
CTX regimen with at least one CTX drug administered intravenously in a cyclic manner (on any 
schedule) for breast, lung, colorectal, prostate, gynecologic, bladder, or testicular cancer or 
lymphoma. Any prior treatment other than surgery was completed at least one month previously, 
and the individual could receive concurrent radiation. Participants had to be able to read and 
write English. Individuals were excluded if their treatment plan included marrow or stem cell 
transplantation, interleukins, interferons, or tumor necrosis factor; had a chronic fatigue disorder; 
were being treated for a diagnosed sleep disorder (such as narcolepsy or sleep apnea); were 
enrolled in another study that involved a psychoeducational intervention; had a communication 
impairment; had overt evidence of psychiatric disorder; or initiated treatment for anemia or 
depression during the previous three weeks. 
 
The Institutional Review Board (IRB) for each study site approved the research protocol in 
conformity to federal regulations. Potential participants were approached by telephone or in the 
clinic, and the study was explained. All study participants provided written informed consent. 
The IRB granted a waiver to retain de-identified demographic information, including age, 
gender, ethnicity, and race, from individuals who refused to participate in the study for 
comparison with study participants. 
 
At each of the recruitment sites, breast cancer patients were the largest cancer population, and 
the group most easily accrued into research because of clinic logistics. Hence, participants in this 
research were stratified by diagnosis (breast cancer vs. non-breast cancer) at each site to ensure 
equivalency of the experimental and control groups on this factor. Participants were then 
randomly assigned to receive either the EASE intervention or the nutrition (control) intervention. 
Random assignments were generated by the statistician and placed in sealed envelopes that were 
numbered and selected sequentially for each stratification group. 
 
Procedures 
Baseline questionnaires measuring subjective symptoms and functional status were completed on 
Day 1 of the CTX cycle before receiving treatment and on Day 4 after the first CTX, which 
coincided with a known time of high fatigue. Also at baseline, an objective measure of sleep 
disturbance (actigraphy) was obtained along with a companion sleep and symptom diary. 
Follow-up data points were Days 43–46 or 57–60 depending on the length of the CTX cycle. At 
both measurement points, patients completed questionnaires and wore the actigraph on the 
nondominant wrist on Day 1 and removed it 72 hours later (which was Day 4, the equivalent of 
three 24-hour periods). 
 
Variables 
Demographic and clinical information was obtained by a questionnaire (age, gender, race, 
ethnicity, marital status, education, employment). Clinical data were abstracted from the medical 
records (diagnosis, stage, comorbidities, previous treatment, and current treatment). 
 
Fatigue was measured with the General Fatigue Scale (GFS), a seven-item Likert-type scale 
(1 = no fatigue, distress, or impact, to 10 = greatest possible fatigue, distress, or impact).25 The 
measure was scored by averaging the responses to the items. Cronbach alpha reliability 
coefficient for this sample was 0.92. 
 
Fatigue also was measured with the fatigue subscale of the Profile of Mood States (POMS) 
questionnaire. The POMS was developed to assess transient distinct mood states. Originally 
designed as a 65-item scale,26 the current short version consisted of six subscales with a total of 
30 items.27 The fatigue symptom subscale (POMS-F) consisted of five adjectives measuring 
subjective fatigue (such as weary, tired, and others) that were rated on a 5-point scale, with “0” 
indicating “not at all” and “4” indicating “extremely.” Items were summed to form a subscale 
score that ranges from 0 to 20. This scale is well recognized as a sensitive, valid, and reliable 
measure of the sensation of fatigue, with considerable evidence of validity and reliability.27,28 
The Cronbach alpha coefficient for this sample was 0.94. 
 
To document subjective sleep disturbance, including insomnia, the Pittsburgh Sleep Quality 
Index (PSQI) was used. The PSQI is a subjective, self-rated, paper-and-pencil questionnaire 
consisting of 19 items. Responses to the 19 items are grouped into seven component scores that 
are weighted equally on a 0–3 scale. The seven components of the PSQI are sleep quality, 
latency, duration, habitual efficiency, disturbances, medication use, and daytime dysfunction. 
The components are summed to produce a global PSQI score that can range from 0 to 21. A 
higher score indicates more severe complaints and worse sleep quality.29 Internal consistency 
reliability and construct validity have been supported in cancer populations.30,31 In this sample, 
the Cronbach alpha reliability for the scale was 0.75. 
 
Objective sleep disturbance data also were obtained by means of continuous noninvasive 
monitoring using wrist actigraphy, an objective record of movement over time in the form of 
activity counts.32,33,34 Actigraphy is a valid, reliable measure of sleep that correlates with 
polysomnography at approximately 90% agreement. It is a sensitive measure of sleep-wake and 
activity-rest patterns as well as circadian activity rhythms. 
 
The actigraph measure used in this research was the Octagonal Basic Motionlogger® Actigraph 
from Ambulatory Monitoring, Inc. (Ardsley, NY). It was an unobtrusive instrument resembling a 
wristwatch that could be worn in the usual environment, both at home and place of employment. 
Instructions about actigraph use included pushing a small marker on the side 1) when putting on 
the actigraph for the first time, 2) when turning out the light to go to sleep, and 3) when getting 
out of bed in the morning. These markers were used to discriminate day from night when 
performing the analysis. 
 
Several sleep-wake parameters were examined in this research: total time in bed (indicated by 
the event markers on the actigraph); total sleep time after sleep onset (in minutes); number of 
awakenings from sleep onset to morning lights on (indicated by an event marker); minutes awake 
(wake after sleep onset [minutes]); and percent time asleep after sleep onset. Data collected 
continuously over 72 hours were uploaded to a personal computer using the Micro-Mini® 
Motionlogger Actigraph Interface Connector and analyzed using the Action 4 analysis program 
(Copyright© 1988–2001; Ambulatory Monitoring, Inc.). Actigraphy data for up to 72 hours were 
analyzed in one-minute epochs. 
 
Participants also completed an adapted Morin Sleep Diary to provide confirmation of “lights off” 
and “lights on” for comparison with the event marker on the actigraph, as well as information 
about naps, medications, and environmental factors that aid in the interpretation of the actigraph 
data. The diary has been used in numerous sleep studies35 in both healthy people and those with 
cancer.36,37,38,39 A test of reliability of actigraphy scoring indicated 83.4% agreement between 
two coders. The intraclass correlation coefficients for each sleep parameter ranged from 0.83 to 
0.99. 
 
Pain severity was measured by the intensity subscale of the Brief Pain Inventory (BPI).40 
Patients reported pain severity (worst, least, average, and current pain) using a 0–10 scale for 
each item (0 = no pain to 10 = pain as bad as you can imagine). The four pain items were 
averaged to yield a pain intensity score ranging from 0 to 10. The scale is widely used; validity 
and reliability in cancer treatment have been established. [40], [41] and [42] Cronbach alpha for the 
BPI intensity scale was 0.88 in this sample. 
 
Depressive symptoms were measured by the depressive symptom subscale of the POMS-D, 
which consisted of five adjectives describing depression (such as sad, discouraged, gloomy, and 
others) rated on a 5-point scale, with “0” indicating “not at all” and “4” indicating “extremely.” 
Items were summed to form a score that ranged from 0 to 20. Internal consistency, as measured 
by Cronbach alpha, was 0.90 in this sample. 
 
Other Side Effects. The side-effect checklist (SCL) is a measure of side-effect severity based on 
a measure used in our previous research on coping with cancer treatment. Severity of side effects 
was rated using a 5-point Likert-type scale (0 = not at all severe to 5 = extremely severe). 
Summed side-effect severity scores have been correlated with outcome measures such as mood 
and other quality-of-life domains in cancer patients.43,44 This instrument has acceptable test-retest 
reliability (r = 0.84) and face validity as well as clinical validity.43,44,45 Cronbach alpha in this 
study was 0.87. 
 
Functional status was assessed by three measures. Limitation of functioning was measured by 
adapting the interference items (SXINT) from the BPI40 to apply to “symptoms” rather than 
“pain” only. Respondents were asked to describe how symptoms had interfered with general 
activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment 
of life. Each item was rated on a 0–10 scale, with the words “did not interfere” at 0 and 
“completely interfered” at 10. Internal consistency reliability for this sample was 0.91. 
 
The Short-Form (SF)-12 provided a second measure of functional status. The SF-12 is a shorter 
version of the 36-item Short-Form Health Survey46,47 that was developed for the Medical 
Outcomes Study.48 The scale includes physical and mental components of quality of life (SF-12-
P and SF-12-M, respectively). Items for each component were recoded (as needed), summed, 
and transformed to a 0–100 scale, with higher scores indicating better physical or mental 
functioning. The scale is widely used in cancer populations, and norms have been established.49 
 
Eastern Cooperative Oncology Group (ECOG) Performance Status is a simple rating of ability to 
function in usual activities. It has been widely used by clinicians to evaluate participants in drug 
clinical trials. It has been adapted here for patient self-report.50 Participants are asked to select 
from five statements the one that best described their current activity level: 1) I have normal 
activity without symptoms; 2) I have some symptoms, but I do not need to spend any extra time 
resting during the day; 3) I need some time to rest (e.g., in bed), but it amounts to less than half 
of my normal daytime; 4) I need to rest (e.g., in bed) for more than half of my normal daytime; 
and 5) I am unable to get out of bed. This item was scored on a 0–4 scale. 
 
 
 
Interventions 
Participants in each intervention group received three telephone sessions with a specially trained 
oncology nurse. The intervention occurred during the second, third, and fourth week after the 
first CTX treatment. Written intervention materials included a handbook specific to the EASE or 
control group. The intervention was delivered using an interactive approach that built on the 
individual's existing knowledge of energy conservation strategies, sleep management, and his or 
her unique response to symptoms. A specific protocol and script were used; however, the nurse 
was trained to customize the protocol to the needs of the participant. 
 
The tenets of the common sense model (CSM)51,52,53 provided the basis for the EASE 
intervention. This model is appropriate for the study of multiple symptoms; it proposes three 
stages of symptom management: representation, coping, and appraisal. In the representation 
stage, the individual gathers information about the symptom's identity, cause, and pattern to form 
a mental image of the symptom. In the coping stage, the individual identifies and implements 
self-care strategies to manage the symptom. During the appraisal stage, the individual evaluates 
the effectiveness of the strategies and adjusts either the coping methods or symptom 
representation based on the experience of symptom management.54 
 
In this study, a research nurse provided symptom management based on the tenets of the CSM. 
Information was provided to assist with the formation of an accurate representation of the 
symptoms of fatigue and sleep disturbance. In the first telephone intervention session conducted 
approximately one week after the first CTX treatment, the research nurse provided information 
to each participant about the characteristics of the two symptoms; typical causes of each (such as 
specific drugs, emotional distress, being over- or underactive); and patterns of symptoms (most 
severe immediately after treatment, tapering off after five to seven days). The nurse engaged the 
participant in a discussion of his or her experience of fatigue and sleep disturbance, including the 
likely causes and patterns during the first week after CTX. EASE group participants also 
received a handbook that included the information about symptoms and examples of energy 
conservation and sleep management strategies. Between Sessions 1 and 2, participants completed 
a daily diary (concerning symptoms and sleep patterns) and a priority list of usual activities. 
 
In the second intervention session during the second week after CTX, the nurse used information 
from the daily diary and priority list to guide the participant to formulate and implement a plan 
of energy conservation to manage valued activities and a plan for sleep enhancement to manage 
sleep disturbance (coping phase). The plan included suggested strategies to manage each of the 
symptoms. Energy conservation strategies for fatigue included decision making about delegating 
activities and responsibilities, pacing oneself, setting priorities, and engaging in demanding 
activities at times of peak energy. Sleep enhancement strategies included establishing an optimal 
environment for sleep; learning and using relaxation techniques to induce sleep at the beginning 
of the night and after nighttime awakenings; restricting sleep to the same number of hours each 
night and minimizing nap taking; and engaging in regular exercise during daytime hours. The 
participant was directed to use the plan during the next week. In the third session (appraisal 
stage), the individual evaluated and revised the plan. 
 
The control intervention was designed to control for the amount of time and attention received 
by the experimental group. The intervention focused on information about nutrition and a healthy 
diet. This content was chosen, because patients with cancer are interested in this topic and 
because it is of minor relevance to fatigue during aggressive cancer treatment.55 Information on 
maintaining a healthy diet was discussed in the first session, including a description of the food 
pyramid and healthy food choices. The participant kept a 24-hour dietary record as homework in 
preparation for the second session. This was discussed during Session 2 for adjustments to their 
diet if needed, and a discussion about vitamins was carried out. The third session consisted of 
sharing information about minerals and fiber as well as an evaluation of the helpfulness of the 
information provided. Therapeutic nutritional information or information on symptom 
management was not included in the control intervention. The three control sessions were 
equivalent to the EASE intervention in terms of the amount of time spent with the individual. 
 
The research nurses at Fox Chase Cancer Center conducted all of the interventions by telephone 
to protect the integrity of the intervention and minimize differences in delivery. Each nurse 
received eight hours of training in the conduct of the EASE intervention. Training included 
didactic presentations as well as demonstration and role play. In addition, ongoing bimonthly 
supervision was provided by one of the investigators. Nurse adherence to the EASE and control 
interventions was examined using a checklist of the components of each intervention. This 
checklist was used to evaluate 20% of the audio-recorded interventions (every fifth case) during 
the first two years of the study to determine adherence to the telephone protocol. Participant use 
of the EASE strategies was measured with a brief checklist of intervention behaviors. Individual 
items were summarized as the number of fatigue and sleep management strategies that were 
used. 
 
Statistical Analysis 
Nonparametric Chi-squared analysis and independent t-tests were used, as appropriate, to 
examine differences between participants and nonparticipants, baseline equivalence between 
study groups (EASE vs. control), and baseline equivalence between participants who completed 
all study activities and those who did not. The SAS Mixed Procedure (PROC MIXED; SAS 
Institute, Cary, NC) restricted maximum likelihood method was used to examine the primary 
hypothesis,56 because the study involved repeated measures that were correlated, and there were 
changes in variability because of attrition. For all analyses, an “intent-to-treat” analysis was 
conducted, in which all available data for participants were included under the missing-at-
random assumption of the mixed-model analysis, and all participants were evaluated as 
randomized regardless of whether they had completed all three intervention sessions. 
 
RESULTS 
One thousand three hundred eleven individuals were assessed for eligibility. Of these, 746 did 
not meet all inclusion criteria, and an additional 273 declined enrollment (Fig. 1). Common 
reasons for not enrolling included lack of interest (n = 107), poor timing (n = 28), inability to be 
contacted (n = 59), and initiation of cancer treatment before consent (n = 33). Two hundred 
ninety-two individuals were enrolled in the study between February 2, 2004, and August 31, 
2007, and were randomized to receive the EASE or control intervention. Sixteen participants 
were excluded from the analysis, leaving 276 analyzed cases. Reasons for exclusion included 
severity of illness (n = 4), loss to follow-up (n = 10), and change of treatment (n = 2). 
 
 
Figure 1: Eligibility, enrollment, and follow-up of study participants. 
 
 
 
A comparison between participants and nonparticipants using Chi-squared and t-tests showed 
that participants (n = 276) and nonparticipants (n = 135) differed significantly with regard to age, 
gender, and cancer diagnosis. Nonparticipants were older and more likely to be males than the 
participants. Breast cancer, and thus, the number of females, was overrepresented in the 
participant group, whereas lung cancer was underrepresented. 
 
The final sample (n = 276) was primarily female (83%), Caucasian (90%), married (70%), 
college educated (42%), and was treated with CTX alone (95%). The most common diagnoses 
were breast (55%), lung (17%), lymphoma (8%), and ovarian (6%) cancers. The mean age was 
53.97 years (standard deviation = 12.02). 
 
Considering the primary outcome variables, patient-reported fatigue (GFS) was moderately 
elevated at baseline and remained elevated at follow-up in both the EASE and control groups 
(Table 1a). Similarly, patient-reported sleep disturbance (PSQI) at baseline and follow-up was 
well greater than the accepted cutoff score of 5 in both groups, indicating moderate levels of 
sleep disturbance. In contrast to patient-reported perception of disrupted sleep, actigraphy 
readings indicated that the total sleep time was almost eight hours, and sleep percent was greater 
than 85% for both groups at both time points, which is in the normal range (Table 1b). Physical 
functioning (SF-12-P) for EASE and control groups at baseline and follow-up was diminished 
and similar to the norms for a sample with serious medical illness,46 as would be expected in this 
sample of cancer patients undergoing treatment. Mental functioning (SF-12-M) was in normal 
range for both groups at both time points. 
 
Table 1a: Means and SDs for Patient-Reported Outcomes 
Measure 
Mean (SD) 
Pretreatment Baseline Day 4 Baseline Follow-Up 
Manipulation check 
CLB 
 EASE 10.03 (3.78)  13.57 (3.1) 
 Control 9.5 (3.62)  12.17 (3.09) 
 Primary patient-reported outcomes 
GFS 
 EASE  5.19 (2.14) 4.89 (1.92) 
 Control  5.12 (2.05) 4.82 (2.03) 
 POMS-F 
 EASE  3.01 (1.13) 2.85 (1.01) 
 Control  3 (1.03) 2.96 (1.12) 
 PSQI 
 EASE 8.01 (3.96)  7.96 (3.59) 
 Control 7.83 (4.37)  8.24 (3.83) 
 SF-12-M 
 EASE 48.95 (10.29)  49.56 (9.64) 
 Control 49.65 (11.11)  49.8 (9.6) 
 SF-12-P 
 EASE 40.3 (11.21)  37.2 (8.97) 
 Control 41.78 (11.37)  37.95 (9.59) 
 Secondary patient-reported outcomes 
BPI 
 EASE  1.99 (2.16) 2.27 (2.26) 
 Control  1.7 (2.14) 2.15 (2.25) 
 POMS-D 
 EASE  1.81 (0.94) 1.63 (0.78) 
 Control  1.95 (0.90) 1.52 (0.66) 
 SCL 
 EASE 0.42 (0.33)  0.65 (0.35) 
 Control 0.42 (0.34)  0.7 (0.42) 
 ECOG-PS 
 EASE 2.03 (0.96)  2.81 (0.81) 
 Control 1.91 (0.94)  2.96 (0.72) 
 SXINT 
 EASE 2.5 (2.34) 3.98 (2.56) 3.76 (2.4) 
 Control 2.5 (2.34) 4.12 (2.57) 3.85 (2.38) 
SD = standard deviation; SXINT = symptom interference; CLB = checklist of behaviors; SCL = side-effect checklist. 
 
 
Because this was a randomized clinical intervention trial, baseline equivalence of the 
intervention groups was examined for the following clinical and demographic variables: cancer 
diagnosis, clinical stage, gender, ethnic background, marital status, education, age, and 
employment status (Table 2). The study groups differed only by employment status—X2 = 4.00, 
P = 0.05. Because employment status could influence the need for and motivation to engage in 
fatigue reduction and/or sleep disturbance reduction behaviors, it was included as an independent 
variable in the main analyses. 
 
 
 
 
 
 
Table 1b: Means and SDs of Actigraphy Parameters Averaged Over Study Days 
Measure 
Mean (SD) 
Day 1–3 Baseline Follow-Up 
Total time in bed (minutes) 
 EASE 543.6 (82.71) 537.82 (93.16) 
 Control 531.73 (81.42) 519.32 (99.47) 
 Total sleep time (minutes) 
 EASE 465.59 (103.92) 466.53 (118.95) 
 Control 465.02 (79.11) 461.97 (100.35) 
 Sleep percent after onset 
 EASE 86.52 (11.55) 87.4 (13.08) 
 Control 88.35 (8.28) 89.48 (8.92) 
 Awakenings 
 EASE 10.47 (5.74) 9.98 (5.46) 
 Control 9.34 (5.41) 8.17 (5.01) 
 Wake after sleep onset (minutes) 
 EASE 69.1 (53.85) 63.63 (63.56) 
 Control 61.3 (44.87) 53.6 (47.09) 
SD = standard deviation. 
 
Of the 276 participants, 60 had some missing data. Baseline equivalence between complete and 
incomplete cases on overall symptom burden (SCL), fatigue (GFS), and functional status (SF-12, 
symptom interference) was conducted using independent-samples t-test. Results show that the 
incomplete cases had worse health at baseline before treatment than those who completed the 
study: SCL (t(270) = 3.212, P = 0.001 [two-tailed]), SF-12 physical (t(271) = 2.346, P = 0.02 
[two-tailed]), SF-12 mental (t(83.70) = 2.034, P = 0.045 [two-tailed]), and symptom interference 
(t(83.93) = 2.756, P = 0.007 [two-tailed]). Complete and incomplete cases did not differ on 
fatigue or sleep disturbance measures. Chi-squared analysis showed no difference in the number 
of complete cases between the two intervention groups—X2 = 0.551, P = 0.458. These findings 
suggest that, in both groups, participants who were in poorer health at baseline were more likely 
to have incomplete data. 
 
One hundred fifty-three participants were allocated to the EASE group and 139 to the control 
group (Fig. 1). Seventy-five percent of the EASE participants and 83% of the control group 
received all three sessions of the intervention. The total amount of intervention time for each 
group was similar (EASE = 69 minutes; control = 72 minutes). A manipulation check was 
conducted to determine whether the EASE and control groups differed in the use of intervention 
strategies. At baseline and follow-up, participants in both study groups completed a behavioral 
checklist; 10 items referred to energy conservation strategies (delegation, planning, pacing, and 
others), and nine items described sleep promotion strategies (using relaxation strategies, avoiding 
caffeine before bedtime, establishing set sleep-and-wake times, others). A repeated measures 
analysis of variance (ANOVA) revealed that the EASE group used significantly more 
intervention strategies over time compared with the control group (Table 3a). This finding 
indicates that the EASE intervention influenced participants as predicted: individuals who were 
taught behavioral strategies to manage fatigue and sleep disturbance reported using more than 
did the control group who were not taught these strategies. 
 
 
 
 
 
 
Table 2: Differences in Demographic and Clinical Characteristics of Study Groupsa 
 EASE Group  Control Group  
Characteristic n (%)  n (%) P-value 
Age (years) (n = 276)    0.42 
 Mean (SD) 54.4 (11.8)  53.5 (12.3)  
  
Gender (n = 276)    0.29 
 Female 114 (80.3)  114 (85.1)  
 Male 28 (19.7)  20 (14.9)  
  
Ethnicity (n = 264)    0.66 
 Non-Hispanic 132 (96.4)  121 (95.3)  
 Hispanic 5 (3.6)  6 (4.7)  
  
Race (n = 272)    0.47 
 American Indian/Alaska Native 3 (2.1)  1 (0.8)  
 Asian 1 (0.7)  2 (1.5)  
 Black or African American 7 (5.0)  11 (8.3)  
 White or Caucasian 127 (90.7)  115 (87.1)  
 More than 1 race 1 (0.7)  3 (2.3)  
 Unknown 1 (0.7)  0 (0)  
  
Marital status (n = 272)    0.39 
 Single 9 (6.4)  13 (9.8)  
 Separated or divorced 24 (17.1)  17 (12.9)  
 Widowed 7 (5.0)  11 (8.3)  
 Married 100 (71.4)  91 (68.9)  
  
Education (n = 271)    0.38 
 8th Grade or less 1 (0.1)  3 (2.3)  
 Some high school 3 (2.1)  8 (6.1)  
 High school graduate or GED 31 (22.1)  24 (18.3)  
 Technical school graduate 6 (4.3)  8 (6.1)  
 Some college 41 (29.3)  32 (24.4)  
 College graduate 58 (41.4)  56 (42.7)  
  
Currently employed (n = 272)    0.05a 
 Yes 69 (49.3)  81 (61.4)  
 No 71 (50.7)  51 (38.6)  
  
Study site (n = 276)    0.79 
 Fox Chase Cancer Center 75 (52.8)  77 (57.5)  
 University of Utah 47 (33.1)  41 (30.6)  
 University of Cincinnati 15 (10.6)  11 (8.2)  
 Christiana Medical Center 5 (3.5)  5 (3.7)  
  
Diagnosis (n = 276)    0.2 
 Breast 73 (51.4)  79 (59.0)  
 Lung 21 (14.8)  26 (19.4)  
 Colorectal 8 (5.6)  5 (3.7)  
 Prostate 2 (1.4)  1 (0.1)  
 Gynecologic 19 (13.4)  13 (9.7)  
 Testicular 0 (0)  1 (0.1)  
 Lymphoma 14 (9.9)  9 (6.7)  
 Bladder 5 (3.5)  0 (0)  
  
Known clinical stage (n = 246)    0.65 
 1 25 (19.7)  19 (16.0)  
 2 47 (37.0)  43 (36.1)  
 3 31 (24.4)  37 (31.1)  
 4 24 (18.9)  20 (16.8)  
aSample size varied by reporting of specific information. 
 
A repeated measures ANOVA was used to test the efficacy of the EASE intervention. Three 
hypotheses were tested. Compared with the control group, it was predicted that the EASE 
intervention group would report: 1) less fatigue over time, 2) less sleep disturbance over time, 
and 3) less disruption of functional status over time. Each measure of the primary outcomes 
(fatigue, sleep disturbance, and functional status) was examined in a separate repeated-measures 
ANOVA (Table 3a). Actigraphy measures of sleep were analyzed in a similar manner (Table 
3b). In each analysis, there was a single between-subject independent variable—study group with 
two levels (EASE or control). In addition, there was a single within-subject variable—time (with 
two occasions of measurement). Current employment was included in the analysis as an 
additional independent variable, because the intervention and control groups differed on this 
variable. The EASE and control groups did not differ on fatigue (GFS and POMS-F), sleep 
disturbance (PSQI and actigraph measures), or functional status (SF-12-M or SF-12-P) over 
time. There were significant three-way interactions for symptom interference (SXINT), pain 
(BPI), and depression (POMS-D), indicating that unemployed individuals who received the 
EASE intervention had less pain and less interference with functioning than employed 
individuals in the same group. Although these differences were statistically significant, the actual 
differences were small and, therefore, not clinically meaningful. 
 
 
Table 3a: F-Test (Repeated-Measures Design with Maximum Likelihood Estimates) and P-
Values for Patient-Reported Outcomes 
Measure df 
Study 
Group Time 
Working 
Status 
Study 
Group by 
Time 
Study 
Group by 
Working 
Status 
Study 
Group by 
Time by 
Working 
Status 
Manipulation check 
 CLB 1/268 6.38a 163.38b 0.00 4.91a 0.00 0.14 
Primary patient-reported outcomes 
 GFS 1/262 0.22 2.91 0.13 0.02 0.06 0.81 
 POMS-F 1/250 0.26 0.95 0.56 0.47 1.29 0.11 
 PSQI 1/265 0.05 0.11 0.30 0.58 0.17 0.00 
 SF-12-M 1/268 0.62 0.00 0.24 0.00 0.49 1.94 
 SF-12-P 1/268 0.84 28.42b 0.18 0.18 0.70 0.74 
 Secondary patient-reported outcomes 
 SXINT (T1a-T1b-T2) 2/268 0.01 46.20b 0.64 0.37 0.00 3.64a 
 SXINT (T1a-T2) 1/268 0.00 46.29b 1.80 0.86 0.53 6.87c 
 SXINT (T1b-T2) 1/260 0.11 0.84 0.63 0.01 0.44 5.17a 
 BPI 1/261 0.94 4.44a 0.65 0.32 0.09 3.95a 
 SCL 1/268 0.29 106.59b 1.85 0.00 0.29 0.00 
 POMS-D 1/184 0.00 16.94b 0.31 1.94 0.01 6.85c 
 ECOG 1/263 0.42 150.82b 4.93a 3.26 3.35 0.07 
SXINT = symptom interference (T1a = Time 1a; T1b = Time 1b); CLB = Checklist of Behaviors; SCL = side-effect checklist. 
aP < 0.05. bP < 0.001. cP < 0.01. 
 
 
Because of the overall null result of the study, we conducted a post hoc subset analysis to 
determine if other factors could have influenced the study results. In separate analyses, gender, 
cancer diagnosis (breast cancer vs. non-breast cancer and lung cancer vs. non-lung cancer), and 
baseline ECOG performance status were added to the linear mixed method analysis as 
independent variables. These analyses (study group-by-covariate-by-time interaction) were used 
to examine whether the intervention benefited a specific group (such as males or females, breast 
or other cancers, and others). Although several of these factors were associated with the primary 
outcomes, there were no significant interactions between these factors and study group 
assignment. 
 
Table 3b: F-Test (Repeated-Measures Design with Maximum Likelihood Estimates) and P-
Values for Patient-Reported Outcomes 
Measure df 
Study 
Group Time 
Working 
Status 
Study 
Group 
by 
Time 
Study 
Group by 
Working 
Status 
Study 
Group by 
Time by 
Working 
Status 
Total time in bed (minutes) 1/251 1.21 0.55 0.64 0.32 0.13 0.31 
Total sleep time (minutes) 1/251 0.00 0.22 1.38 0.17 0.96 0.09 
Sleep percent after onset 1/251 1.71 3.52 8.47b 0.07 0.80 0.04 
Number of awakenings 1/251 2.78 4.99a 0.33 1.39 0.17 1.46 
Wake after sleep onset (minutes) 1/251 1.50 4.76a 8.12b 0.12 0.80 0.05 
aP < .05. bP < .01. 
 
 
DISCUSSION 
The study results indicate that the EASE intervention did not improve fatigue, reduce sleep 
disturbance, or prevent functional decline during CTX. Both intervention and control groups 
demonstrated an increase in fatigue and decline in physical functioning. There was no difference 
over time between the intervention and control groups despite the fact that the EASE 
intervention group reported using more behavioral intervention strategies that had been taught 
than the control group. A positive outcome in both groups was a decrease in the average number 
of nighttime awakenings over time. The finding that unemployed individuals benefited more 
from the EASE intervention than those who were employed raises questions about the burden 
associated with behavioral interventions for individuals who continue to work during cancer 
treatment. 
 
The results are puzzling, because a previous intervention trial3 of fatigue management using the 
energy conservation (ECAM) component of the current intervention demonstrated a modest 
reduction of fatigue during treatment. This follow-up study built upon that successful 
intervention by introducing an additional intervention component that was proposed to have a 
more powerful beneficial effect on fatigue, sleep disturbance, and functional status than was 
previously observed. 
 
To make sense of the study results, we have considered several potential explanations. The first 
possibility is that differences in the design of the two studies could have influenced the outcome. 
In fact, there were four important differences between the two studies: type of cancer treatment, 
complexity of CTX regimens, amount of intervention provided, and timing of the outcome 
measures. 
 
In the previous ECAM clinical trial, 47% of the sample received CTX, 44% had radiotherapy, 
and 9% got both treatment modalities concurrently. The two groups that received CTX had more 
severe fatigue and worse functional status over time than the radiotherapy group. It is possible 
that the radiotherapy group benefited more from the ECAM intervention and contributed more to 
the improvement of fatigue scores than the CTX groups. Despite the EASE intervention, a 
significant increase in fatigue and sleep disturbance and a decline in functional status occurred 
from before to after CTX. It is possible that the intervention was not powerful enough to 
overcome the negative effect of CTX on symptoms and functioning. 
 
Another difference between the two studies is that the number and complexity of CTX regimens 
has changed dramatically over the years. In the previous study, most cytotoxic CTX was given 
on a 21- or 28-day schedule, with drugs given on the first day by bolus or infusion followed by a 
three- or four-week recovery period. In the EASE study, CTX regimens were more variable, 
intensive, and complex. The oxaliplatin and infusional 5-fluorouracil (FOLFOX) regimen for 
colorectal cancer involved a 48-hour infusion every 14 days; sometimes, the biologic, 
bevacizumab, also was given. Dose-dense CTX for breast cancer consisted of four 14-day cycles 
of doxorubicin and cyclophosphamide followed by four 14-day cycles of paclitaxel; in some 
cases, trastuzumab was given with paclitaxel. For participants who received this regimen, the 
final data collection point coincided with the first cycle of paclitaxel. Some CTX regimens for 
lung cancer were given weekly; others were given every week for three weeks followed by one 
week of recovery. All of these treatment variations could have increased the intensity of 
treatment-related symptoms such that an intervention focused on only two symptoms was no 
longer powerful enough to be effective. In fact, our measure of other treatment side effects 
demonstrated a dramatic increase in the intensity of symptoms over time and wider variability in 
the number and intensity of symptoms reported by study participants. It is also possible that the 
variability of CTX regimens resulted in different patterns of fatigue and sleep disturbance for 
each regimen. 
 
A third difference between the two studies was the amount of behavioral intervention provided. 
In both trials, the intervention was conducted by telephone in three separate sessions. The 
previous intervention was focused on providing information about fatigue and teaching energy 
conservation skills. In the current trial, information was provided about both fatigue and sleep 
disturbance; both energy conservation and sleep modification strategies were taught. It is 
possible that the amount of time spent in the intervention (intervention dose) for the EASE 
condition was insufficient for individuals to develop skill in using both energy conservation and 
sleep improvement strategies as well as to incorporate these strategies into their daily lives. 
 
Another potential explanation for the lack of intervention effectiveness could be the number of 
intervention sessions received by participants (dose). Only three intervention sessions were 
conducted in contrast to other intervention trials for multiple symptoms. [19], [20] and [21] In those 
studies, more sessions appeared to equate with more consistent benefit from the intervention. A 
meta-analysis has also suggested that 8–10 sessions of psychoeducational intervention are 
needed to achieve maximal behavior change.57 
 
A fourth difference in the two studies was the timing of the outcome measures. In the previous 
ECAM trial, measurements were taken before the first CTX cycle and three days after the second 
and third CTX treatments. Fatigue scores measured before the initiation of CTX were lower than 
the two measurements taken after the next two CTX sessions. Reasoning that fatigue and sleep 
disturbance could be elevated before and after CTX, baseline measures of the primary outcomes 
in the current study occurred before treatment and four days after CTX treatment. Then, changes 
in the primary outcomes (if present) would be more clearly attributed to the EASE intervention. 
Despite the improved study design, we did not observe the expected decrease in fatigue and sleep 
disturbance or improvement of functional status for the EASE group, indicating that the 
intervention did not have the predicted effect. Given the complexity and variability of the CTX 
regimens in this study, it is possible that the timing of our measures did not capture symptom 
changes because of the intervention, because individuals receiving weekly or biweekly therapy 
may have an up-and-down pattern of symptoms corresponding to each dose of CTX.58 
 
Another potential explanation for the result is the possibility that a large number of participants 
had low fatigue and/or sleep disturbance or symptoms that were not severe enough to 
demonstrate improvement because of the EASE intervention. Three days after the first CTX 
treatment, 29% of the EASE sample reported fatigue scores less than 4 on a 1–10 scale, 
indicating that almost one-third of study participants had a low level of fatigue. Likewise, 50% 
of participants rated their usual sleep quality as “fairly good” or “very good” before intervention; 
also, actigraph results demonstrated that two-thirds of the sample had sleep efficiency ratings 
(the ratio of time asleep and total time in bed) of 85% or greater three days after CTX, which is 
considered normal. This suggests the presence of a “floor” effect that could have influenced 
study results; it also argues against the assumption that everyone who gets CTX will have a high 
level of fatigue or sleep disturbance requiring intervention. 
 
Future Directions 
Several lessons learned form the basis for recommendations for future symptom management 
studies. We noted that the timing of measures was not optimal in the context of the complex 
treatment regimens that were used in the EASE study. There are at least two ways to approach 
this problem. First, it may be possible to limit variability by limiting study eligibility to a few 
diagnoses and treatment regimens. However, this may still leave considerable variability. Using 
the example of breast cancer treatment, one study noted 16 regimens, at least four of which were 
commonly used.24 It is also likely that new regimens will continue to be introduced during the 
course of a symptom management trial. A second approach would be more frequent monitoring 
of symptoms. However, this approach also has deficiencies with regard to patient burden and 
adherence. It is critical to identify efficient and simple methods for symptom monitoring, such as 
automated systems.59,60,61,62,63 
 
Another issue that needs exploration is the amount or “dose” of symptom intervention. 
Intervention efficacy could be related to the dose of intervention (number and frequency of 
intervention sessions); yet, little is known about the dose of intervention needed to alleviate 
multiple symptoms. Although most behavioral intervention studies have described the 
“intended” time or amount of intervention, few studies have examined the “actual” amount of 
intervention delivered. It is not clear whether an optimal dose of intervention is a fixed amount 
or a variable dose that is adapted to symptom severity. Future intervention trials would benefit 
from an exploration and by possibly tailoring the intervention dose. In addition, trials involving a 
tailored intervention targeting symptoms as part of a symptom cluster would be beneficial. 
 
Attention also must be paid to symptom severity as a potential eligibility criterion for symptom 
management trials. A run-in period could be used to monitor symptoms so that a minimum level 
of symptom severity can be documented for eligibility to participate. Finally, it may be necessary 
to compare a symptom intervention with a usual-care control group. 
 
Despite the lack of positive findings from this clinical trial, it is essential to continue to examine 
behavioral interventions for symptom management during CTX. There are several reasons for 
this recommendation. First, many individuals with multiple symptoms during CTX could benefit 
from effective behavioral interventions. “Behavioral” interventions are identified, because 
symptom management focuses primarily on patient behavior. Although medication may be 
prescribed for a symptom, symptom management focuses on the use of drugs and behavioral 
strategies for optimal benefit. Second, the results of previous research suggest that benefit can be 
derived from symptom management conducted over time by skilled nurses. [19], [20] and [21] Further 
research could inform nurses of the most effective management methods to control symptoms. 
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